Sun Pharma Advanced Research Company Limited
NSE: SPARC BSE: SPARC
NSE
135.19
-1.76 (-1.29%)
Prev Close
136.95
Open Price
136.09
Volume
196,488
Today Low / High
134.35 / 136.79
52 WK Low / High
109.3 / 241
Range
128 - 142
BSE
135.05
-2.00 (-1.46%)
Prev Close
137.05
Open Price
136
Volume
19,891
Today Low / High
134.85 / 136.5
52 WK Low / High
109.2 / 240.95
Range
128 - 142
The stock is currently trading on both the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE). On the NSE, the stock is priced at 135.19 (target range: 128 - 142), reflecting a change of -1.76 (-1.28514%). On the BSE, it is listed at 135.05 (target range: 128 - 142), showing a change of -2 (-1.45932%). The stock price is currently in decline on both exchanges, signaling a downtrend. If you're considering investing in this stock, it's important to monitor the situation closely.
31 Oct
136.09
-0.66%
30 Oct
138.00
-0.76%
29 Oct
142.00
-3.01%
28 Oct
133.99
6.15%
27 Oct
132.00
0.95%
24 Oct
131.99
-0.47%
23 Oct
132.80
-0.61%
21 Oct
130.01
1.38%
20 Oct
129.40
0.47%
17 Oct
132.30
-2.19%
16 Oct
132.00
-0.13%
15 Oct
130.50
0.60%
14 Oct
134.20
-2.79%
13 Oct
134.00
0.16%
10 Oct
130.00
3.08%
09 Oct
128.05
-0.02%
08 Oct
130.44
-1.83%
07 Oct
131.90
-1.11%
06 Oct
132.10
-0.14%
03 Oct
133.00
-0.67%
Sun Pharma Advanced Research Company Limited Graph
Sun Pharma Advanced Research Company Limited Price Target Predictions: Bullish vs. Bearish Scenarios with Ranges
If you are looking for the target price for Sun Pharma Advanced Research Company Limited T1, T2, T3 for both Bullish and Bearish scenarios, here it is. For Bullish: T1, T2, T3. For Bearish: T1, T2, T3. The stock current price is 135.19, with potential price targets ranging from T1, T2, and T3 in both directions based on market conditions.
| Scenario | Price | Target | Range |
|---|---|---|---|
| Bullish Scenario | 135.05 | 136.40 | 122.76 - 150.04 |
| 137.75 | 110.20 - 165.30 | ||
| 139.10 | 97.37 - 180.83 | ||
| Bearish Scenario | 135.05 | 133.70 | 120.33 - 147.07 |
| 132.35 | 105.88 - 158.82 | ||
| 131.00 | 91.70 - 170.30 |
Overview of Sun Pharma Advanced Research Company Limited
ISIN
INE232I01014
Industry
Drug Manufacturers - Specialty & Generic
Vol.Avg
370,513
Market Cap
43,872,073,482
Last Dividend
0
Official Website
IPO Date
2003-01-14
DCF Diff
183.51
DCF
-48
Financial Ratios Every Investor Needs
Annual Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | R&D Expenses | G&A Expenses | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 71.77 Cr | 23.12 Cr | 48.65 Cr | 0.6779 | 81.33 Cr | 91.72 Cr | -277.98 Cr | -342.51 Cr | -10.55 | -323.14 Cr | -4.7723 |
| 2024-03-31 | 75.55 Cr | 199.37 Cr | -123.82 Cr | -1.6391 | 479.34 Cr | 152.46 Cr | -411.50 Cr | -387.21 Cr | -11.93 | -373.15 Cr | -5.1256 |
| 2023-03-31 | 238.78 Cr | 171.58 Cr | 82.12 Cr | 0.3439 | 452.84 Cr | 131.95 Cr | -223.64 Cr | -222.58 Cr | -7.82 | -203.18 Cr | -0.9322 |
| 2022-03-31 | 137.25 Cr | 126.70 Cr | 10.55 Cr | 0.0769 | 324.00 Cr | 69.52 Cr | -196.91 Cr | -203.40 Cr | -7.73 | -179.90 Cr | -1.4819 |
| 2021-03-31 | 252.96 Cr | 206.40 Cr | 46.56 Cr | 0.1840 | 387.93 Cr | 51.93 Cr | -145.90 Cr | -151.14 Cr | -5.77 | -129.57 Cr | -0.5975 |
Annual Financials Balance Sheet
| Date | C&C Equ. | Tot. Assets | Tot. Liab. | Stock. Equity | Tot. Debt | Net Debt | Inv. | PP&E (Net) | Curr. Def. Rev. | Non-Curr. Def. Rev. | LT Invest. | Curr. Liab. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 1.96 Cr | 335.53 Cr | 552.48 Cr | -216.9500 Cr | 268.92 Cr | 266.96 Cr | 0.00 Cr | 99.26 Cr | 0.00 Cr | 62.60 Cr | 25.64 Cr | 374.2400 Cr |
| 2024-03-31 | 5.33 Cr | 515.04 Cr | 389.29 Cr | 125.7554 Cr | 61.15 Cr | 55.82 Cr | 0.00 Cr | 108.62 Cr | 16.68 Cr | 103.49 Cr | 25.02 Cr | 265.0578 Cr |
| 2023-03-31 | 0.58 Cr | 830.12 Cr | 317.35 Cr | 512.7700 Cr | 15.67 Cr | 15.09 Cr | -4.17 Cr | 107.28 Cr | 18.22 Cr | 117.65 Cr | -228.64 Cr | 178.9400 Cr |
| 2022-03-31 | 1.22 Cr | 280.08 Cr | 248.86 Cr | 31.2257 Cr | 79.21 Cr | 77.99 Cr | 0.00 Cr | 95.12 Cr | 0.03 Cr | 66.85 Cr | 11.52 Cr | 171.4289 Cr |
| 2021-03-31 | 9.30 Cr | 229.69 Cr | 397.94 Cr | -168.2516 Cr | 236.38 Cr | 227.08 Cr | 3.32 Cr | 95.11 Cr | 9.80 Cr | 39.24 Cr | 0.00 Cr | 233.3517 Cr |
Annual Financials Cash Flow Statement
| Date | Operating Cash | Investing Cash | Financing Cash | Free Cash | Cash Change | Cash at End | CapEx | Income | Debt Repay | Dividends | Inventory |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | -360.2900 Cr | 157.6600 Cr | 199.2500 Cr | -370.6300 Cr | -3.3695 Cr | 1.9600 Cr | -10.3400 Cr | -342.5100 Cr | 211.1853 Cr | 0.0000 Cr | 0.0000 Cr |
| 2024-03-31 | -429.1883 Cr | 391.5271 Cr | 42.4051 Cr | -455.6962 Cr | 4.7459 Cr | 5.3295 Cr | -26.5079 Cr | -387.2139 Cr | 46.9490 Cr | 0.0000 Cr | 0.0000 Cr |
| 2023-03-31 | -69.1200 Cr | -548.2800 Cr | 616.7600 Cr | -84.5100 Cr | -0.6400 Cr | 0.5800 Cr | -15.3900 Cr | -222.5800 Cr | -74.9490 Cr | 0.0000 Cr | 0.0019 Cr |
| 2022-03-31 | -208.2325 Cr | -29.1670 Cr | 229.3209 Cr | -240.9104 Cr | -8.0803 Cr | 1.2242 Cr | -32.6779 Cr | -203.3954 Cr | -155.5452 Cr | 0.0000 Cr | 0.0000 Cr |
| 2021-03-31 | -151.8956 Cr | 1.5618 Cr | 159.2843 Cr | -157.8907 Cr | 8.9522 Cr | 9.3045 Cr | -5.9951 Cr | -151.1388 Cr | 169.4405 Cr | 0.0000 Cr | 0.0000 Cr |
Quarterly Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|
| 2025-06-30 | 9.64 Cr | 10.67 Cr | -1.03 Cr | -0.1068 | -54.76 Cr | -51.87 Cr | -1.60 | -42.94 Cr | -5.3807 |
| 2025-03-31 | 27.19 Cr | 5.70 Cr | 21.49 Cr | 0.7904 | -56.13 Cr | -59.77 Cr | -1.84 | -53.03 Cr | -2.1982 |
| 2024-12-31 | 14.91 Cr | 30.36 Cr | -15.45 Cr | -1.0362 | -76.83 Cr | -79.51 Cr | -2.45 | -73.50 Cr | -5.3327 |
| 2024-09-30 | 12.86 Cr | -74.87 Cr | 87.73 Cr | 6.8219 | -106.07 Cr | -107.33 Cr | -3.31 | -102.87 Cr | -8.3460 |
| 2024-06-30 | 16.81 Cr | 61.93 Cr | -45.12 Cr | -2.6841 | -96.50 Cr | -95.90 Cr | -2.96 | -91.80 Cr | -5.7049 |
Quarterly Financials Balance Sheet
| Date | Cash & Equiv. | Short-Term Inv. | Cash & Short-Term | Net Receivables | Inventory | Total Curr. Assets | PP&E (Net) | Total Assets | Total Liabilities |
|---|---|---|---|---|---|---|---|---|---|
| 2025-06-30 | 0.00 Cr | 0.00 Cr | 1.96 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 216.95 Cr |
| 2025-03-31 | 1.96 Cr | 0.00 Cr | 1.96 Cr | 16.06 Cr | 0.00 Cr | 26.19 Cr | 99.26 Cr | 335.53 Cr | 552.48 Cr |
| 2024-12-31 | 0.00 Cr | 0.00 Cr | 6.07 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 77.38 Cr |
| 2024-09-30 | 5.67 Cr | 0.40 Cr | 6.07 Cr | 13.61 Cr | 0.00 Cr | 90.55 Cr | 104.65 Cr | 320.81 Cr | 398.19 Cr |
| 2024-06-30 | -157.13 Cr | 314.26 Cr | 157.13 Cr | 0.00 Cr | 0.00 Cr | 157.13 Cr | 0.00 Cr | 0.00 Cr | -125.76 Cr |
Quarterly Financials Cash Flow Statement
| Date | Net Income | Operating Cash Flow | Investing Cash Flow | Financing Cash Flow | Net Cash Change | Cash at End | Cash at Beginning | CapEx | Free Cash Flow |
|---|---|---|---|---|---|---|---|---|---|
| 2025-06-30 | -51.87 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2025-03-31 | -59.77 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-12-31 | -79.51 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-09-30 | -107.33 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-06-30 | -95.90 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
Splits History
| Date | Label | Split Ratio |
|---|---|---|
| 2012-08-23 | August 23, 12 | 127:125 |
Similar Stocks: Drug Manufacturers - Specialty & Generic
| Company Name | Symbol | Price | Market Cap | Volume |
|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | SUNPHARMA | ₹1,690.70 | ₹4,056,549,508,373.00 | ₹1,560,907.00 |
| Divi's Laboratories Limited | DIVISLAB | ₹6,738.00 | ₹1,788,732,898,056.00 | ₹507,645.00 |
| Torrent Pharmaceuticals Limited | TORNTPHARM | ₹3,560.10 | ₹1,204,898,044,500.00 | ₹354,021.00 |
| Dr. Reddy's Laboratories Limited | DRREDDY | ₹1,197.60 | ₹996,839,216,220.00 | ₹4,250,056.00 |
| Mankind Pharma Limited | MANKIND | ₹2,384.00 | ₹984,016,240,160.00 | ₹593,366.00 |
| Zydus Lifesciences Limited | ZYDUSLIFE | ₹974.45 | ₹980,520,395,716.00 | ₹458,971.00 |
| Lupin Limited | LUPIN | ₹1,963.50 | ₹896,844,333,000.00 | ₹1,017,447.00 |
| Aurobindo Pharma Limited | AUROPHARMA | ₹1,138.90 | ₹661,474,968,435.00 | ₹3,556,831.00 |
| Alkem Laboratories Limited | ALKEM | ₹5,506.50 | ₹658,384,672,500.00 | ₹178,327.00 |
| Glenmark Pharmaceuticals Limited | GLENMARK | ₹1,891.20 | ₹533,698,169,981.00 | ₹398,054.00 |
| Laurus Labs Limited | LAURUSLABS | ₹953.65 | ₹514,804,014,931.00 | ₹1,545,364.00 |
| Suven Pharmaceuticals Limited | SUVENPHAR | ₹1,078.00 | ₹412,407,234,624.00 | ₹1,177,218.00 |
| Ipca Laboratories Limited | IPCALAB | ₹1,271.20 | ₹322,508,801,922.00 | ₹106,442.00 |
| Ajanta Pharma Limited | AJANTPHARM | ₹2,465.30 | ₹308,003,793,847.00 | ₹102,941.00 |
| Cohance Lifesciences Limited | COHANCE | ₹753.40 | ₹288,226,083,276.00 | ₹1,868,840.00 |
| J. B. Chemicals & Pharmaceuticals Limited | JBCHEPHARM | ₹1,682.30 | ₹263,441,852,870.00 | ₹161,890.00 |
| Piramal Enterprises Limited | PEL | ₹1,124.20 | ₹254,856,250,172.00 | ₹2,148,582.00 |
| Emcure Pharmaceuticals Ltd. | EMCURE | ₹1,318.90 | ₹250,017,076,708.00 | ₹201,166.00 |
| AstraZeneca Pharma India Limited | ASTRAZEN | ₹9,555.00 | ₹238,875,000,000.00 | ₹20,033.00 |
| Eris Lifesciences Limited | ERIS | ₹1,591.70 | ₹216,811,113,902.00 | ₹40,393.00 |
| Neuland Laboratories Limited | NEULANDLAB | ₹16,473.00 | ₹211,346,761,497.00 | ₹44,604.00 |
| Wockhardt Limited | WOCKPHARMA | ₹1,281.50 | ₹208,224,272,482.00 | ₹289,135.00 |
| Alembic Pharmaceuticals Limited | APLLTD | ₹897.40 | ₹176,395,747,478.00 | ₹69,233.00 |
| Jubilant Pharmova Limited | JUBLPHARMA | ₹1,101.00 | ₹174,564,413,184.00 | ₹543,954.00 |
| Caplin Point Laboratories Limited | CAPLIPOINT | ₹2,032.80 | ₹154,516,575,629.00 | ₹43,860.00 |
| NATCO Pharma Limited | NATCOPHARM | ₹819.90 | ₹146,852,182,413.00 | ₹412,467.00 |
| Granules India Limited | GRANULES | ₹565.60 | ₹137,253,425,770.00 | ₹384,397.00 |
| Glenmark Life Sciences Limited | GLS | ₹1,086.00 | ₹133,070,838,000.00 | ₹130,938.00 |
| Alivus Life Sciences Ltd. | ALIVUS | ₹904.45 | ₹110,959,145,199.00 | ₹27,710.00 |
| Procter & Gamble Health Limited | PGHL | ₹6,152.00 | ₹102,119,398,064.00 | ₹17,413.00 |
| Strides Pharma Science Limited | STAR | ₹934.70 | ₹86,153,835,776.00 | ₹9,219,602.00 |
| Aarti Pharmalabs Limited | AARTIPHARM | ₹851.95 | ₹77,214,757,940.00 | ₹105,286.00 |
| FDC Limited | FDC | ₹460.65 | ₹74,998,465,195.00 | ₹252,540.00 |
| Akums Drugs & Pharmaceuticals Ltd. | AKUMS | ₹460.75 | ₹70,541,773,224.00 | ₹53,334.00 |
| Shilpa Medicare Limited | SHILPAMED | ₹352.85 | ₹69,011,043,776.00 | ₹149,611.00 |
| Sequent Scientific Limited | SEQUENT | ₹214.61 | ₹53,633,796,524.00 | ₹1,034,635.00 |
| Gujarat Themis Biosyn Ltd. | GUJTHEM | ₹465.10 | ₹50,679,744,752.00 | ₹51,856.00 |
| Innova Captab Limited | INNOVACAP | ₹831.10 | ₹47,559,638,492.00 | ₹13,222.00 |
| Aarti Drugs Limited | AARTIDRUGS | ₹491.10 | ₹44,822,697,000.00 | ₹54,690.00 |
| Sun Pharma Advanced Research Company Limited | SPARC | ₹135.19 | ₹43,872,073,482.00 | ₹196,488.00 |
| Suven Life Sciences Limited | SUVEN | ₹197.55 | ₹43,073,939,692.00 | ₹121,404.00 |
| RPG Life Sciences Limited | RPGLIFE | ₹2,403.90 | ₹39,758,138,159.00 | ₹6,281.00 |
| Orchid Pharma Limited | ORCHPHARMA | ₹726.30 | ₹36,837,285,962.00 | ₹86,074.00 |
| Unichem Laboratories Limited | UNICHEMLAB | ₹470.95 | ₹33,157,587,963.00 | ₹3,282.00 |
| Gufic Biosciences Limited | GUFICBIO | ₹325.40 | ₹32,631,927,452.00 | ₹54,623.00 |
Key Executives
Company Secretary & Compliance Officer
Ms. Kajal K. Damania
Gender: female
Year Born:
Senior General Manager of Business Development, Corporate Communication & Investor Relations
Mr. Jaydeep Issrani
Gender: male
Year Born:
Chief Human Resource Officer
Ms. Shanta Gupta
Gender: female
Year Born:
Head Clinical Development
Mr. Siu-Long Yao
Gender: male
Year Born:
Chief Operating Officer
Dr. Nitin Dharmadhikari
Gender: Not Specified
Year Born: 1962
Chief Innovation Officer
Dr. Nitin K. Damle Ph.D.
Gender: Not Specified
Year Born:
Head of Drug Delivery Systems
Dr. Yashoraj Zala
Gender: Not Specified
Year Born:
Chief Financial Officer
Mr. Anup Rathi
Gender: male
Year Born:
Chief Executive Officer
Mr. Anilkumar Raghavan
Gender: male
Year Born: 1968
Head of Preclinical Development
Dr. Vikram K. Ramanathan
Gender: Not Specified
Year Born:
FAQs about Sun Pharma Advanced Research Company Limited
Who is the CEO of the company?
The CEO is Anilkumar Raghavan.
What is the current market price of the stock?
The current price is ₹135.19.
What is the 52-week price range?
The range is ₹109.3-241.
What is the market capitalization of the company?
The market capitalization is ₹4,387.21 crores.
What is the Price-to-Earnings (P/E) ratio?
The P/E ratio is -14.68.
Which sector does the company belong to?
The company operates in the Healthcare sector.
What does the company do?
Overview of Sun Pharma Advanced Research Company Limited (ISIN: INE232I01014) is a leading Drug Manufacturers - Specialty & Generic in India. With a market capitalization of ₹4,387.21 crores and an average daily volume of 370,513 shares, it operates in the Drug Manufacturers - Specialty & Generic. The company last declared a dividend of ₹0.